Valacyclovir: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Robert Badgett
Line 13: Line 13:


==Usage==
==Usage==
Valacyclovir can reduce the frequency of recurrence of [[herpes labialis]] from [[herpes simplex virus]].<ref name="pmid12661753">{{cite journal| author=Baker D, Eisen D| title=Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. | journal=Cutis | year= 2003 | volume= 71 | issue= 3 | pages= 239-42 | pmid=12661753  
Valacyclovir can reduce the frequency of recurrence of [[herpes labialis]] from [[herpes simplex virus]].<ref name="pmid12661753">{{cite journal| author=Baker D, Eisen D| title=Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. | journal=Cutis | year= 2003 | volume= 71 | issue= 3 | pages= 239-42 | pmid=12661753 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12661753 }} </ref><ref name="pmid18541820">{{cite journal| author=Cernik C, Gallina K, Brodell RT| title=The treatment of herpes simplex infections: an evidence-based review. | journal=Arch Intern Med | year= 2008 | volume= 168 | issue= 11 | pages= 1137-44 | pmid=18541820 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18541820 | doi=10.1001/archinte.168.11.1137 }} </ref>
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12661753 }} </ref>
 
Valacyclovir can reduce the frequency of recurrence of [[herpes genitalis]]  from [[herpes simplex virus]].<ref  name="pmid18541820">{{cite journal| author=Cernik C, Gallina K,  Brodell RT| title=The treatment of herpes simplex infections: an  evidence-based review. | journal=Arch Intern Med | year= 2008 | volume=  168 | issue= 11 | pages= 1137-44 | pmid=18541820 |  url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18541820  | doi=10.1001/archinte.168.11.1137 }} </ref>


==External links==
==External links==

Revision as of 22:36, 12 July 2010

In pharmacology and virology, valacyclovir (Valtrex) is "a prodrug of acyclovir; 53% of oral dose excreted as acyclovir in the urine; a 200-400% improvement on acyclovir; used in the management of HSV and VZV infections and the prophylaxis of HCMV infections; RN given refers to the monohydrochloride L-valine isomer."[1]

History

Valtrex brand of valacyclovir was approved by the Food and Drug Administration in the United States with a New Drug Application (NDA) in 1995.[2] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2007.[3]

Pharmacology

Administration

Distribution

Metabolism

Excretion

Toxicity

Drug toxicity includes

Usage

Valacyclovir can reduce the frequency of recurrence of herpes labialis from herpes simplex virus.[4][5]

Valacyclovir can reduce the frequency of recurrence of herpes genitalis from herpes simplex virus.[5]

External links

The most up-to-date information about Valacyclovir and other drugs can be found at the following sites.

References

  1. Anonymous (2024), Valacyclovir (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Drugs@FDA. U S Food and Drug Administration
  3. Drugs@FDA. U S Food and Drug Administration
  4. Baker D, Eisen D (2003). "Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.". Cutis 71 (3): 239-42. PMID 12661753.
  5. 5.0 5.1 Cernik C, Gallina K, Brodell RT (2008). "The treatment of herpes simplex infections: an evidence-based review.". Arch Intern Med 168 (11): 1137-44. DOI:10.1001/archinte.168.11.1137. PMID 18541820. Research Blogging. Cite error: Invalid <ref> tag; name "pmid18541820" defined multiple times with different content